Jamie Cesanek, Assistant Web Editor for CURE®, joined the team in March 2021. She graduated from Indiana University Bloomington, where she studied journalism and minored in sociology and French. In her free time, she enjoys hiking, running, or enjoying time with friends and family. Email her at jcesanek@curetoday.com.
Higher BMI in Adulthood May Limit the Immune System’s Ability to Fight Breast Cancer
January 14th 2022New findings demonstrated that adult patients with breast cancer and increased BMI had an association with different types of immune cells around their tumors that may affect how their body attacks the cancer cells.
A Lower Dose of Xpovio May Help Patients With Myeloma Get the ‘Full Benefit of the Drug’
January 13th 2022Although patients with multiple myeloma may be concerned that a reduction in treatment dose may be less effective, an expert from The Tisch Cancer Institute stresses that it may be more beneficial.
‘Shock to the Heart’: A Cancer Survivor Recalls the Emotions of Her First Chemo Treatment
January 12th 2022After not knowing quite what to expect from her first chemotherapy treatment, colorectal cancer survivor Yla Flores describes the pain she felt in her heart after seeing other patients in worse conditions.
Trial Launched to Assess Safety and Efficacy of Novel Drug in Rare Type of Head and Neck Cancer
January 10th 2022A phase 2 trial was recently launched to examine the safety and efficacy of oral inhibitor VK-2019 in patients with advanced Epstein-Barr Virus-positive nasopharyngeal carcinoma, a rare type of head and neck cancer, and lymphoma.
Expert Explores the Relationship Between Down Syndrome and Leukemia
January 6th 2022In this episode of the “Cancer Horizons” podcast, an expert unpacks cancer risks for individuals with Down syndrome and analyzes the results of a recent study about mortality risks for childhood survivors later in life.
Keytruda/Chemo Combo Is ‘Great News’ for Patients With TNBC, ‘But We Need Much More’
January 6th 2022An expert discusses improvements in survival outcomes for patients with triple-negative breast cancer who received Keytruda plus chemotherapy — now considered the standard of care — but urges that more researched is always needed for this patient population.
Trial Underway to Assess Efficacy of Novel Radiopharmaceutical Drug in Neuroendocrine Tumors
January 5th 2022The phase 3 COMPOSE trial will look at the efficacy of using 177lu-edotreotide — a novel radiopharmaceutical that is designed to limit radiation exposure to normal tissue — in patients with later stage neuroendocrine tumors.
The Last Patient: Cancer Survivor Recounts Diagnosis as COVID-19 Closed Clinicians’ Doors Worldwide
December 23rd 2021On this episode of the “Cancer Horizons” podcast, a colorectal cancer survivor explains how she was the last patient to receive a colonoscopy leading to her stage 3 diagnosis as her doctor’s office shut down because of COVID-19 in March 2020.